Friday, November 13, 2009

Rules of Engagement: FDA Considers Guidelines Around Social Media

After spending the last two days in a conference room, our existence sustained only by sandwiches, caffeine and the occasional oxygen tank provided by the interns, we have emerged from the FDA social media hearing trenches bright eyed and excited for things to come, yet our minds are filled with several unanswered questions.

What did we learn?

Guidelines are needed and are needed soon. We heard many companies share their frustration and reluctance to participate in social media because of uncertainty around what they can and cannot do. While attempting to be responsible, this does not help patients who are seeking accurate information and need help sifting through online media, which can be a breeding ground for inaccurate, false and even dangerous information.

And yet we heard that empowered, informed patients have better dialogue with their doctors, greater understanding of their health conditions, which can lead to better outcomes. In many case, pharmaceutical companies have access to the information the healthcare community needs. Patients like to know they are being heard. The problem is too many companies are listening and not doing enough about what they are hearing.

So how can we facilitate communications? How can we make this happen?

One take home message: It is time for a paradigm shift. In case you haven’t noticed, in social media less is more. And the more relevant the information to the conversation taking place, the better. Perhaps we all need to take a lesson from Twitter on how to communicate. Maybe we challenge ourselves to highlight the key ISI and fair balance information in 140-characters or less. Those who want more information can take a deeper dive if they desire.

Luckily, studies seem to show that the online healthcare community wants and even welcomes information from the pharmaceutical industry but not without rules of engagement. Clearly, links to small print and disclaimers - as one speaker termed it “truth dumping” – is not the right way to engage. It’s true, one-way, one-sided communication is not what social media is about. It is a two-way dialogue with meaningful, relevant, tailored responses that improve communications and make the difference.

Social media levels the playing field. No longer do you have to have tons of money to be heard. Patients have a voice, but now we need to take the muzzle off the pharmaceutical industry to stop these one-way conversations to nowhere.

What can we do in the meantime?

Right now, we need to become experts in the technologies that are out there now. And we should keep a close eye out for emerging technologies as they become available. What's next?

We also believe companies that are not currently participating in social media should start engaging right away. Missing the boat now before the new wave hits will mean missed opportunities for dialogue and a will certainly mean a long trip on a ferry to catch up.

How long will it take before we see guidelines?

Fortunately, the FDA is keeping the docket open until February 28, 2010. This will ensure they are able to really dive deep into the information, as several presenters conducted valuable research or referenced key studies in their recommendations.

The FDA noted that once the docket closes the organization will consider carefully all the information submitted by its stakeholders.

What does this mean in real time? Realistically, we do not believe new guidelines will be implemented till at least 2011. There is a large amount of information that must be digested, and this issue is too important to rush a decision.

The FDA must take the time understand and evaluate current technologies available, such as hash tags, widgets and hovering boxes, that allow pharmaceutical companies to engage in the social media dialogue while providing patients with useful and safety information. It is also important for the FDA to keep the pulse on emerging technologies. The social media space is growing so quickly that guidelines based on the social media landscape of 2010 could hinder the pharmaceutical companies’ participation in 2011 and beyond.

Note: To submit documents for consideration before the docket closes, submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments, identified with docket number FDA-2009-N-0441, to http://www.regulations.gov.